American scientists have suggested that cholesterol screening programs are too restricted and should include greater number of children and young adults.

Current guidelines set by the American Academy of Pediatrics recommend that children and adolescents with a family history of early-onset heart disease or high cholesterol or already identified risk factors such as obesity or diabetes should be screened for high cholesterol.

However, a new study has pointed out that many people do not know their accurate medical history. They examined 20,000 children in the West Virginia area, both asking for their family histories and testing their cholesterol levels.

The team discovered that more than 71% of the children had family histories that suggested they should be screened for high cholesterol, while 9.5% of those children with no significant family histories also had high cholesterol. 1.7% of those children with high cholesterol but with no family history needed medication to treat the condition.

The findings have resulted in calls for all children to be routinely screened for high cholesterol, not just those with a family history. The authors of the report, published in the journal Pediatrics, have concluded that current screening guidelines result in 36% of children with high cholesterol being missed.

In Britain, a similar study in 2007 called for children to be screened at 15 months. Current guidelines state that screening should take place in under-40s only when they have particular risk factors for the condition.

Could cholesterol levels be related to the messages sent by the brain and not just to what we eat? This is what a new study has suggested.

Researchers have discovered that cholesterol levels can be affected by the release of the hormone ghrelin, which affects hunger, calorie intake and how much energy we expend. The team noticed in mice that when the levels of ghrelin increased, so did the levels of bad cholesterol in their blood.

This had lead them to conclude that ghrelin regulates the amount of cholesterol released by the liver. A separate test showed that blocking the release of the hormone also caused cholesterol levels in the blood to rise.

The hormone has been described as a ‘remote control’ for the cholesterol travelling around the body.

The lead researcher on the project, Professor Matthias Tschoep, said that until now scientists thought that cholesterol was exclusively regulated by fats absorbed from diet or by secretions from the liver. The findings have shown for the first time that there is also a direct control system in the central nervous system.

The researchers are planning on doing tests involving humans to see if the same reaction is observed. If this is the case, it could lead to the development of a new way of treating high cholesterol.

Currently, statins are the first-line treatment given to those with high cholesterol. It is also crucial for people to take regular exercise, stay slim and eat a low-fat diet.

Though a Mediterranean diet has long been thought to raise the levels of good cholesterol in the body, a study has suggested that some people who suffer heart attacks could have genetic markers which make their diet increase the risk of cardiac problems.

The team discovered that those with high levels of the ‘good’ cholesterol HDL, which is associated with a diet rich in olive oil, nuts and oily fish, has a higher risk of suffering further heart attacks. The people involved had higher levels of the protein CPR, associated with inflammation, which suggested that the protein determined whether high levels of HDL acted as a protection or increased the risk of a heart attack.

The results have been described as ‘counter-intuitive’ by lead researcher Professor James Corsetti of the University of Rochester in New York. However they do perhaps explain why a medication trialled by Pfizer designed to raise levels of HDL cholesterol had disappointing results.

In this study, 767 patients who had had a heart attack were followed for two years. About 20% of the patients who were at high risk of a second heart attack also had high levels of HDL and CRP.

The team have suggested that if doctors and researchers can identify those people who do not benefit from raised levels of HDL, they could properly test medications to raise HDL levels in the rest of the population.

Merke announced in 2011 that they were planning to test an HDL-increasing medication to see whether it reduced incidences of stroke and heart attack.

A study by scientists from the University of Nottingham has led calls for doctors to prescribe the lowest dose of statins when treating patients with high cholesterol, to lower risk of adverse events.

Published in the British Medical Journal, the primary care study showed that the chance of adverse events was increased in different degrees depending on the type, dose and duration of the statins administered.

The team used data taken from 369 general practices, containing the medical records of 2 million patients newly prescribed statins. This included 225,922 patients taking either simvastatin, atorvastatin, fluvastatin, pravastatin or rosuvastatin to reduce cholesterol.

Over 8 years, any adverse reaction were recorded. For every 10,000 women at high-risk who were treated with statins, there would be 74 cases of liver damage, 23 cases of kidney failure and 307 cases of cataracts. However, this increased risk was offset by the fact that in the group, there would be 271 fewer cases of heart disease and 8 fewer cases of cancer of the oesophagus.

Doctors have always been aware that statins, like any medication, come with the risk of side effects. However it is generally thought that the risk of side effects is offset by the reduction in cases of heart disease, stroke and other illnesses.

A spokeswoman from the British Heart Foundation, June Davison, said that they were already aware that a small proportion of statin users experience side effects, but that for those at high risk of heart disease, this chance was outweighed by the potential benefits.

Following similar approval in the U.S, drug firm Astra-Zeneca has won approval from European regulators to market their cholesterol-lowering statin to a far wider group of patients.

This means that in 19 European Union countries, the firm will be able to market the product to a far wider patient group. Industry analysts have said that while approval is likely to result in increased sales of the drug, the upcoming expiry of Pfizer’s patent over statin Lipitor in 2011 may affect that, as it will presage the arrival of cheaper generics on the market.

The ruling means that Crestor can now be prescribed to patients thought to be at risk of a first heart attack. The decision comes after further analysis from the Jupiter study, which involved nearly 18,000 patients. It showed that people with elevated levels of the protein C-reactive benefited from treatment with Crestor and reduced their overall risk of experiencing an event like a heart attack or stroke.

Previously Crestor was approved for use in patients with high levels of the ‘bad’ cholesterol LDL, which is strongly linked to an increased risk of atheroscelerosis. This is when fatty plaques build up in the blood vessels, increasing the risk of blood flow to the heart being blocked.

Michael Cressman, who is the executive director for clinical research at Astra Zenica, described the decision as a ‘significant milestone’.

Though many food companies have cut down on the amount of transfats they include in their food, UK public health experts have called for a total ban on the ingredient.

Writing in the British Medical Journal, scientists estimated that the solid fats, found in margarine, cakes and junk food, were responsible for a significant number of deaths each year. They estimated that were there to be a 1% reduction in UK consumption, 7,000 deaths each year could be prevented.

Transfats are added to food to improve taste and shelf life, but they do not have any nutritional value. Studies have shown that they can raise cholesterol levels and lead to heart disease.

Earlier this year, the UK facility of Public Health warned that through the average UK resident’s transfat intake only makes up 1% of their daily calorie intake, in some areas and communities, the intake is far higher, putting those groups at risk. Scientists believe that when intake exceeds 2%, the consumer is risking their health.

The Food Standards Agency currently say that as the UK’s average intake is in the safe zone, a total ban is unnecessary.

However in the article, doctors from the Harvard Medical School supported the ban, pointing to the bans in Denmark and New York City which they said had improved health without affecting taste or affordability.

Professor Alan Maryon-Davies of the UK Faculty of Public Health said that his organisation was particularly concerned by the differences in the amount of transfats consumed amongst societal groups and said that young people and those with low incomes were particularly at risk of consuming large amounts of the fats.

A study recently published in the New England Journal of Medicine has dashed hopes that intensive work to drive down cholesterol levels in diabetic patients could reduce heart problems.

The study was part of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, which was designed to see whether drug therapy to reduce cholesterol and blood pressure could make a difference to the higher risk diabetics have of developing heart problems .

Diabetics are thought to be twice as likely as those without the condition to suffer from heart attacks. Generally they are put on medication to reduce the risk, with doctors aiming to lower blood pressure and levels of LDL cholesterol in the blood.

However the researchers have released very surprising data which has showed that such treatments do not in fact cut the risk of heart disease in diabetic patients. Results from the trial, launched ten years ago, showed that lowering the high blood pressure to very low levels did not decrease the number of patients experiencing heart attacks, strokes, or death from cardiovascular causes.

Patients who were taking statins were given an additional drug known as a fibrate which lowers triglycerides while boosting levels of  the ‘good’ cholesterol HDL. Unfortunately, again this did not affect levels of heart attacks, strokes and heart-related death.

The results seemed to show that patients in all groups faced a 2% increased risk of having a cardiovascular event regardless of whether they were receiving intensive treatment to lower blood pressure, a fibrate as well as a statin or a statin alone.

Nonetheless doctors have stressed that though the findings are surprising, patients with diabetes still need to keep their cholesterol and blood pressure levels under control through exercise and diet and should not stop taking any medication without consulting their doctor first.

Even the president of the U.S is not immune to the health problems that afflict most of us as we get older – apparently Barack Obama has slightly raised cholesterol.

Reporters were surprised when after taking the presidential motorcade to give a speech on Monday, the President chose to walk back to the White House through Layfayette Park in Washington. He told them that he was trying to walk of his cholesterol, which he attributed to the year spent campaigning.

He revealed that after having a physical exam on Sunday his doctor told him that the levels of the ‘bad’ cholesterol LDL in his blood had risen to the borderline level (meaning they were becoming a concern) since his last exam in 2007.

White House spokesperson Robert Gibbs said that the rise was a result of too many cheeseburgers and desserts. He joked with reporters that though they all thought Obama was very conscious about his health and ‘carried arugula in his pocket to snack on’, the president actually has a very sweet tooth.

He said that as Obama has access to kitchen staff and a pastry chef, sweet foods were more available so the president was more likely to indulge his love of desserts.

It is not known whether the president will be starting on statins to lower his cholesterol.

The physical also revealed that President Obama has still not managed to quit smoking, though he has previously spoken about his struggles to give up. Mr. Gibbs said that he was very aware of the example he sets to America’s youth and knows that his addiction is not a ‘good thing’ for either his children or those throughout the States to see.

We tend to think of junk food, obesity and high cholesterol as a problem of the modern age – but apparently the ancient priests of Egypt caused as much damage to their health as we do today/

According to Egyptologists and scientists writing in The Lancet the priest’s diet, rich in fatty foods, alcohol and red meat, meant that they suffered from heart disease and tended to die early.

In ancient Egypt, the priests were expected to placehuge plates of food before the statues of the gods three times a day, in order to appease them.The gods were offering massive quantities of roasted birds, cakes, bread and oceans of beer and wine – but then the food would be divied up between the priests for them to take home to their families.  Much of the menu was extremely high in saturated fat.

The University of Manchester scientists combined translations of inscriptions on the temple walls with analysis of the priest’s mummified remains, to work out how bad their atheroscelerosis (or build up of fatty plaques in the arteries) was.

They showed that the priests were suffering from high cholesterol long before Macdonalds and fried chicken became such a problem. Of the 16 mummies they examined, 9 showed signs of atheroscelerosis. It is thought that for the peasants who made up the majority of the population, living off cereals and vegetables, high cholesterol was very far from being a problem.

Some unscrupulous priests could even be accused of deserving everything they got, after inscriptions indicated that they would take the food without even offering it to the gods.

Professor Tony Heagerty said that the findings showed that the modern plague of cholesterol is ‘nothing more than history revisiting us’, as unequivocally ‘atherosclerosis is a disease of ancient times.’

A research group in the UK have claimed that the use of statins increases the chances of someone developing diabetes. However they said that the risk of diabetes was outweighed by the benefits that statins provide.

The team analysed data from 13 different trials, were statins were prescribed to over 90,000 patients. Of those patients, over 4,000 went on to develop type 2 diabetes during the 4 years the average patient was monitored for. The study was published in the Lancet.

Taking a statin according to the study put patients at a 9% higher risk of developing diabetes compared with those who were not on statin treatment. This was the equivalent of 1 person amongst 255 patients taking statins for 4 years of developing diabetes.

The researchers particularly noticed that for older patients, there seemed to be a stronger association between diabetes and statins. However there seemed to be no greater risk dependant on the type of statin used.

Statins are widely prescribed to lower cholesterol levels in patients, generally above 40 years of age. They have been shown to dramatically reduce the chances of someone experiencing a heart attack or stroke, as high cholesterol can cause blockages in the heart due to the build up of fatty deposits in the arteries.

The lead researcher, Professor Naveed Satar, professor at Glasgow University  of metabolic medicine, said that clinical practice in the treatment of cardiovascular problems would not change, regardless of the findings of the study. He said that the “small absolute risk” of developing the condition was outweighed by the reduction in risk for strokes and heart attacks.

A leading heart surgeon has called for butter to be banned, saying that the move would dramatically lower the cholesterol rates of the nation and cut down the number of people developing heart disease.

Dr Shyam Kolvekar, a surgeon at University College Hospital, has said that he has grown increasingly worried about the number of patients he is seeing who need heart surgery due to a diet high in saturated fats, including patients has young as 30.

A saturated-fat heavy diet increased cholesterol dramatically, which itself causes fatty deposits to build up which can eventually block the flow of blood to the heart, causing heart attacks and strokes. Each year cardiovascular disease causes 198,000 deaths in Britain each year and costs the economy £7.9 billion.

Dr. Kolvekar said that if the UK were to ban butter and use a replacement, low-cholesterol spread instead, the average daily fat intake would be reduced by 8 grams, or 40% of a woman’s Guideline Daily Fat amount.

The Daily Mail however published a quote from the celebrity chef Jamie Oliver, who is famous for using butter fairly frequently in his cooking. He apparently doesn’t like the whole kind of "food police" and pointed out that butter can be eaten in moderation.

Dr. Kolvekar’s rather militant views on the creamy spread might be explained by the fact that his comments were distributed to the press by KTB, Flora margarine spread’s PR company. They say that he is not receiving any payment however and that he genuinely does believe butter should be banned.

As for us, while the doctor absolutely has a point in saying that many people are developing heart problems due to ‘lifestyle choices’ and we firmly believe the nation needs to pay far more attention to diet, moderation is the key. Processed and junk foods are a far bigger threat than a bit of Lurpack from time to time.

Despite the data from the study having been released over a year ago, scientists analysing the Jupiter study into the cholesterol-lowing statin, Crestor, say that is could be of special benefit to women.

Last year Jupiter gathered data on thousands of people to see whether the statin drug could be beneficial for them. It was shown that Crestor reduced by 45% the risk of having a heart attack, stroke, bypass or dying from cardiovascular disease.

Now after studying information on the 6,801 women who took part in the trial they have discovered that while men taking part saw their risk of experiencing an adverse heart event reduced by 42% this jumped to 46% in women.

Presenting the new data at the American Heart Association meeting in Orlando, the director for AstraZeneca’s Director for Crestor Clinical Development, said that women had been underrepresented in clinical trials into statins and previously there had been limited evidence that women could benefit from statin therapy. He added that the Crestor study was the first to show a significant reduction in cardiovascular risk in women wth no previous history of heart disease.

At the moment, statins are some of the most widely-prescribed drugs on the market. There is fierce competition amongst the pharmaceutical companies as to which one their products achieves market dominance and doubtless Astra-Zeneca are hopeful that their research will give them the lead when it comes to marketing.

We all know lowering cholesterol is good for the health of our heart, reducing the risk of developing heart disease or experiencing a stroke. Now scientists believe lower cholesterol could also reduce a person’s chances of developing certain cancers.

According to one of the studies published this week in the journal Cancer Epidemiology, Biomarkers and Prevention low cholesterol is associated with a 60% reduced risk of developing the most aggressive form of prostate cancer. 

5,586 men aged 55 or over were studied as part of a large cancer prevention study begun in the 1990s. They discovered that there was a “striking reduction in risk”, as the accompanying editorial put it, of developing the aggressive form of the cancer.

A second study was also published which showed that high levels of the ‘good’ cholesterol HDL could protect against liver, lung and other cancers.

Average levels of HDL cholesterol are about 50mg/dL on average for men, but in the first study it was shown that those men with HDL cholesterol above 55 were 11% less likely to develop cancer.  This result was based on data taken from 29,000 Finnish male smokers over an 18-year-period.

While the scientific world is excited about the results, it has been agreed that more work needs to be done to get clearer answers about the relationship between cholesterol and cancer. Previous reports have suggested that statins can reduce cancer rates, but again there are no definitive answers about this.  

A leading health expert has warned that Britain faces a ticking time bomb over the growing number of people developing heart disease due to high cholesterol.

Dr. Andrew Carson, a senior lecturer in general practice at Birmingham University, has warned that high cholesterol could be leaving the UK with an ‘uncontrollable epidemic’ unless a creative solution to the problem is found.

He described how heart problems are already costing the NHS £14 billion a year and said that a more imaginative solution needed to be found to treat them.

He has called for more money to be spent on finding alternatives to statins, the cholesterol lowering drugs that are currently prescribed to large sections of the over-40 s population. He said that as they do not always work for cardiovascular patients, an alternative was needed, suggesting that there needs to be more research into the compound in tomatoes, believed to be responsible for making the Mediteranean diet so healthy.

He wants the NHS to fund research into a compound called Ateronon, based on lycopene, the tomato compound. He has said that this compound could provide a cheaper alternative to statins, on which £500,000 million is spent each year.

The cholesterol problem has been exacerbated by rising obesity levels, poor diet and an increasingly sedentary lifestyle in England. Though money has been channelled into raising awareness of healthy living, the message is proving hard to get though, with experts suggesting that by 2050, 90% of children at the moment could have weight problems.

A team of scientists have said that they believe that cholesterol is important for the development of brain cells, findings they hope will lead to the development of new treatments for Parkinson’s Disease.

In a study published in this month’s edition of Cell Stem Cell, the international research group showed that mice needed an oxidised form of cholesterol, oxysterol, to allow dopamine-producing brain cells to activate a receptor.

Their research, based on stem cells, also showed that when embryonic stem were treated with oxysterol they were able to create more dopamine-producing cells . Stem cells also have a tendancy to grow uncontrollably and the team believe treatment with cholesterol stopped this undesirable growth.

The lead scientist Professor Ernest Arenas from the Centre for Developmental Biology and Regenerative Medicine in Sweden and colleagues from Australia, the US and the UK concluded that treating embryonic human stem cells with the oxidised cholesterol could improve stem cell treatments for Parkinson’s by “selectively augmenting” the amount of dopamine-producing neurons.

Their ultimate aim is to one day replace the dead cells in the brain of Parkinson’s patients with cells producing dopamine which have been grown in a lab. The lab-created cells could also be used to test potential new treatments for the debilitating disease.

Scientists have warned that men with high cholesterol and those who smoke may be risking their life span being cut short by ten years compared to their healthy counterparts.

The study, which was based in the UK, showed that men with unhealthy lifestyles could be seriously curtailing their life expectancy. The researchers from Oxford University examined data taken from 19,000 civil servants aged between 40 and 69 and then followed them to discover what happened to them over 30 years later.

They discovered that there were three risk factors that had a serious impact on how long they lived, which were: high blood pressure; high cholesterol; and whether or not they smoked. All three are strongly associated with the lifestyle choices people make, as both high cholesterol and high blood pressure are often caused by an unhealthy diet and lack of exercise.

Published in the British Medical Journal, the study was originally set up in the late 1960s, a period when vascular heart disease was rife. The civil servants had their heaight, weight, blood pressure, cholesterol and blood glucose measures taken and were then asked about their lifestyle and medical history.

When they were traced in 2005, 13,501 of the volunteers had died. The scientists discovered that there was a 15 year life expectancy difference between the 5% with the lowest risk factors and the 5% with the highest risk factors.

The team said that their findings showed that men aged 50 with the three risk factors could expect to live to 74, which those with no risk factors were likely to survive until 83. They added that men who took steps to reduce the risk factors in their life, by attempting to lower their blood pressure and cholesterol and stop smoking, could expect to significantly prolong their lives.

The connection between unhealthy living and erectile dysfunction has long been highlighted by the medical community and the media. However, new research from The Second University of Naples has established that women should be wary too due to a strong link between high cholesterol and female sexual dysfunction.The research found that women who had high cholesterol had not only their general health affected but also their ability to be sexually aroused. High cholesterol, also known as hyperlipidemia, causes arteries to get blocked restricting the flow of blood around the body. As with men, women need an increase in blood flow to their sexual organs in order to achieve good sexual functioning.